Your browser doesn't support javascript.
loading
[Progress in treatment of primary mediastinal large B-cell lymphoma].
Chen, L W; Li, J Y; Fan, L.
Afiliação
  • Chen LW; Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
  • Li JY; Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
  • Fan L; Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Zhonghua Xue Ye Xue Za Zhi ; 45(1): 98-102, 2024 Jan 14.
Article em Zh | MEDLINE | ID: mdl-38527847
ABSTRACT
Primary mediastinal large B-cell lymphoma (PMBCL) is an aggressive B-cell lymphoma originating from the thymus, which has different clinical and biological characteristics from diffuse large B-cell lymphoma, NOS. PMBCL tends to occur in young women, usually presenting as a large anterior mediastinal mass. Most patients are in stage Ⅰ-Ⅱ at the time of presentation. There is no standard prognostic scoring system for PMBCL. Immunochemotherapy is commonly used in the treatment of PMBCL, but the optimal first-line treatment has not been determined, and the status of radiotherapy is controversial. The value of PET-CT guided therapy needs to be further verified. Relapsed/refractory PMBCL has a poor prognosis, while novel therapies such as PD-1 inhibitors, brentuximab vedotin, and CAR-T can help improve survival in these patients.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Neoplasias do Mediastino Idioma: Zh Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfoma Difuso de Grandes Células B / Neoplasias do Mediastino Idioma: Zh Ano de publicação: 2024 Tipo de documento: Article